Physician profile
Eugene E Stec
NPI 1245260207
$3,794.22
in general payments reported to CMS, 2019-2025
23 companies · $909 in 2025
The $909 reported for 2025 was more than what 77% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $295 · 2021: $581 · 2022: $901 · 2023: $599 · 2024: $15.80 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,424 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.26 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $720.05 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $640.46 | 2019-2025 | |
| Optinose US, INC. | $440.96 | 2019-2023 | |
| Glaxosmithkline, LLC. | $415.61 | 2021-2025 | Nucala |
| Acclarent, INC | $312.15 | 2019-2022 | |
| Inspire Medical Systems, INC. | $226.36 | 2025 | Inspire |
| Stryker Corporation | $173.47 | 2019-2025 | Xpress Loprofile |
| Kaleo, INC. | $126.69 | 2019-2021 | |
| Alk-Abello, INC | $121.79 | 2021-2023 | Ragwitek, Grastek, Odactra |
| Sanofi-Aventis U.S. LLC | $99.99 | 2023 | |
| Aerin Medical INC. | $98.96 | 2019-2023 | |
| Integra Lifesciences Corporation | $69.44 | 2022-2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Medtronic, INC. | $68.24 | 2025 | Propel |
| Intersect Ent, INC. | $53.19 | 2020-2021 | |
| Incyte Corporation | $46.75 | 2023 | Opzelura |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $46.38 | 2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $27.94 | 2025 | Cuvitru |
| Organogenesis INC. | $26.22 | 2022 | |
| Hikma Pharmaceuticals USA | $18.03 | 2023 | Kloxxado, Ryaltris |
| Abbvie INC. | $17.71 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $15.80 | 2024 | Andexxa |
| Paratek Pharmaceuticals, INC. | $14.37 | 2025 | Xhance |
| Merck Sharp & Dohme LLC | $13.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Stec listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.